Teaching

Presentation of QUIBIM Precision platform at PARENCHIMA meeting in Prague, October 2018

QUIBIM continua su liderazgo en imagen médica e inteligencia artificial gestionando los datos y los algoritmos de un proyecto europeo en 25 países

QUIBIM ha sido seleccionado como el socio principal para gestionar todos los datos de imagen médica y los algoritmos de análisis de la iniciativa PARENCHIMA, un proyecto europeo de la acción COST (European Cooperation in Science and Technology) que se inició en abril de 2017 con el objetivo de impulsar el uso de biomarcadores de imagen calculados con resonancia magnética para mejorar el manejo de pacientes con enfermedad renal crónica. Multiples Investigadores científicos de 25 países europeos, líderes en imagen médica y enfermedad renal, utilizarán en esta iniciativa la plataforma QUIBIM Precision® para la realización de análisis avanzados. Uno de los desafíos del proyecto es centralizar los datos de imágenes médicas y los algoritmos de todos los socios para permitir la comparación entre protocolos de adquisición y algoritmos computacionales en términos de calidad y precisión. El resultado del proyecto consistirá en dos nuevos estándares para la adquisición y análisis de imágenes de resonancia magnética en la enfermedad renal crónica.

En la pasada reunión anual en Praga, los días 4 y 5 de octubre, se formalizó el acuerdo entre los socios del consorcio PARENCHIMA y QUIBIM. La plataforma QUIBIM Precision fue seleccionada como el mejor sistema para la gestión de las imágenes y de integración de los nuevos algoritmos de análisis.

Steven Sourbron, profesor de resonancia magnética en la Universidad de Leeds y coordinador del proyecto, manifestó: “Estoy encantado de que QUIBIM haya elegido asociarse con PARENCHIMA para ayudarnos a mejorar los resultados en beneficio de los pacientes, al hacer accesibles estas innovadoras y prometedoras técnicas para su uso en ensayos clínicos y manejo asistencial del paciente”. Frank Zöllner, profesor adjunto de física médica en la Universidad de Heidelberg y líder del grupo de trabajo encargado de la base de datos y el software de PARENCHIMA, comentói que “QUIBIM tiene una gran experiencia en algoritmos de inteligencia artificial y gestión de datos de imagen médica y estamos seguros de que son el colaborador adecuado que necesita este proyecto”. Angel Alberich-Bayarri, CEO de QUIBIM expresó que “QUIBIM está orgulloso de ser parte de este proyecto donde se generarán nuevos estándares de adquisición y análisis de imágenes en la enfermedad renal crónica, un escenario clínico no abordado previamente de forma conjunta. El impacto de este estudio será global y mejorará la vida de millones de pacientes, ya que esta enfermedad afecta al 10% de la población mundial.”

 

Acerca de PARENCHIMA

Hoy en día, los biomarcadores de resonancia magnética renal están infrautilizados no sólo en la investigación, pero también en la práctica clínica, principalmente debido a la falta de difusión y a la necesidad de desarrollo de técnicas propias. Transferir soluciones a otros centros donde funcionen y estén validadas es, por lo tanto, un reto todavía no resuelto, lo que conlleva una replicación significativa de esfuerzos, una falta de estandarización en los métodos y dificultades para comparar los resultados entre los centros. Esto también limita la comercialización y dificulta la creación de ensayos multicéntricos y la traslación a la práctica clínica.

El objetivo general de PARENCHIMA es eliminar las principales barreras para un estudio clínico más extenso y la consiguiente explotación comercial de los biomarcadores de resonancia magnética renal.

PARENCHIMA coordinará la investigación de los principales grupos europeos en esta área para:

  • mejorar la reproducibilidad y estandarización de los biomarcadores de resonancia magnética renal;
  • aumentar su disponibilidad desarrollando un conjunto de herramientas de acceso abierto con herramientas software y datos;
  • demostrar la validez biológica y la utilidad clínica en un estudio clínico prospectivo multicéntrico.

Para aumentar el impacto de este proyecto, hemos decidido unir nuestros esfuerzos. Más información en: www.renalmri.org

 

Sobre QUIBIM

QUIBIM es una empresa de Valencia (España) que aplica inteligencia artificial y modelos computacionales avanzados a las imágenes radiológicas para medir de manera objetiva los cambios producidos por una lesión o por los tratamientos farmacológico, y ofrece información cuantitativa adicional al enfoque cualitativo de la radiología. La tecnología y los servicios de QUIBIM se aplican en la práctica clínica, los ensayos clínicos, la formación en radiología y los proyectos de investigación. Más información en: www.quibim.com

Presentation of QUIBIM Precision platform at PARENCHIMA meeting in Prague, October 2018

QUIBIM to manage imaging data and AI for European project PARENCHIMA across 25 countries

QUIBIM has been selected as the main partner to manage all imaging data and analysis algorithms of the PARENCHIMA initiative, a COST action project initiated in April 2017 with the objective of boosting the use of renal MRI biomarkers to improve the management of chronic kidney disease patients. The leading scientific researchers in medical imaging of the kidney from 25 European countries will be using QUIBIM Precision® platform for highly advanced image analysis. One of the challenges of the project is to centralize the medical imaging data and algorithms from all partners to allow for acquisition protocols and algorithms comparison in terms of quality and precision. The outcome of the project will consist of two new standards for image acquisition and analysis in MR of the kidney.

In the past annual meeting of the consortium in Prague, which took place on 4-5 October, an agreement was established between QUIBIM and PARENCHIMA consortium partners for the selection of QUIBIM Precision platform as the best system for images management and integration of new analysis algorithms.

Steven Sourbron, Lecturer in Magnetic Resonance Imaging at the University of Leeds and project coordinator, expressed “I am delighted that QUIBIM has chosen to partner with PARENCHIMA, helping us to improve outcomes for patients by opening up these promising new methods for use in clinical trials and patient management”. Frank Zöllner, adjunct Professor for medical physics at the University of Heidelberg and leader of working group for PARENCHIMA database and software said “QUIBIM has strong expertise in AI algorithms and managing data and we are confident that they are the right collaborator for this project”. Angel Alberich-Bayarri, CEO of QUIBIM said that ”QUIBIM is excited to be part of this project, which will lead to new standards of image acquisition and analysis in Chronic Kidney Disease (CKD), an unaddressed clinical scenario. I am confident that the impact of this study will be global and improve lives of millions of patients, since it is a disease affecting 10% of population worldwide”

 

About PARENCHIMA

Renal MRI biomarkers are today underused in research and in clinical practice due to the need for dedicated in-house expertise and development. Transferring solutions to other centres is therefore a challenge, and this leads to a significant duplication of efforts, a lack of standardisation in the methods, and difficulties in comparing results between centres. This also limits commercial exploitation, and hinders the set-up of multi-centre trials or translation into clinical practice.

The overall aim of PARENCHIMA is to eliminate the main barriers to the broader study, commercial exploitation and clinical use of renal MRI biomarkers.

PARENCHIMA will coordinate the research of leading European groups in this area to:

  • improve the reproducibility and standardisation of renal MRI biomarkers;
  • increase their availability by developing an open-access toolbox with software and data;
  • demonstrate biological validity and clinical utility in a prospective multicentre clinical study.

In order to increase the impact of this project we are reaching out to join the efforts. More info at: www.renalmri.org

 

About QUIBIM

QUIBIM is a company from Valencia (Spain) which applies artificial intelligence and advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology. QUIBIM technology and services are applied in clinical practice, clinical trials, radiology education and research projects. More info at: www.quibim.com

Visit of the group of Dr. Regina Beets-Tan and Dr. Erik Ranschaert to QUIBIM headquarters

The satisfaction of bringing together the best experts in the world at home

Dr. Luis Martí-Bonmatí (QUIBIM co-founder and director of advisory board) and myself had been locally organising the joint congress of the European Society of Oncological Imaging (ESOI) and the European Society of Medical Imaging Informatics (EuSoMII) for approximately 1 year, and the event finally took place past October from 6th to 8th at our home. The Venue was our hospital: La Fe Polytechnics and University Hospital, where we develop our professional activity and where QUIBIM headquarters are placed, since QUIBIM is a spin-off Company of La Fe Health Research Institute, the institutional arm of the hospital to perform research.

The topic of the congress was “Imaging Informatics in Oncology” and it was the result of joining both Societies fields like Oncology and Medical Imaging Informatics from ESOI and EUSOMII, respectively. The congress program combined workshops with plenary sessions. The workshops covered different concrete areas like Response to treatment, Tumor Boards, 3D printing, and Imaging Informatics for clinicians and computer scientists. The complete program can be found here.

I had the opportunity to present on our stepwise development of Imaging Biomarkers process and the associated bottlenecks for validation. Here you can find the slides of the presentation.

Our group had a really active participation, either from the Biomedical Imaging Research Group (GIBI230) from our Hospital and from QUIBIM.

The main scientific presentations were:

  1. ProstateChecker, a tool for the multi-variate analysis of Prostate Cancer from T2, diffusion and perfusion MR sequences, by David García-Juan, post-processing biomedical engineer at QUIBIM
  2. Cloud architecture for Imaging Biomarkers analysis, by Rafael Hernández, CTO at QUIBIM
  3. Spatial registration on PET-CT scans and quantitative structured report for treatment response evaluation on lymphoma patients, by Fabio García-Castro, post-processing biomedical engineer at QUIBIM
  4. Web application for PI-RADS 2.0 Structured Reporting, by Enrique Ruiz-Martínez, CTO at GIBI230 group
  5. Business analytic, metric, key performance indicator. Automating the monitorization of performance indicators in Radiology departments, by Enrique Ruiz-Martinez, CTO at GIBI230 group
  6. Platform for the integration of Imaging Biomarkers in Radiology Departments, by Enrique Ruiz-Martinez, CTO at GIBI230 group
  7. Integration of Redmine as a tool to manage Clinical Trials in Radiology, by Amadeo Ten-Esteve, Clinical Trial Manager at GIBI230 group.
  8. Artificial intelligence techniques applied to medical imaging. Deep learning applied to automated chest X-ray screening, by Belén Fos-Guarinos, internship biomedical engineering student at GIBI230 group.
  9. Automatic vertebrae localization in pathological spine CT using Decision Forests, by Ana Jiménez Pastor, internship telecommunications engineering student at QUIBIM.
  10. Automated segmentation of muscle using Neural Networks, by Sara Rocher, internship biomedical engineering student at GIBI230 group.
  11. Automatic classification of intensity-vs-time curves in breast DCE-MRI by K-means clustering and Dynamic Time Warping curve matching, by Fabio García-Castro, post-processing biomedical engineer at QUIBIM

In the meantime, the QUIBIM stand was boiling! With several experts interested…

QUIBIM CEO, Angel Alberich-Bayarri explaining QUIBIM advantages to interested attendees to EUSOMII - ESOI congress

QUIBIM CEO, Angel Alberich-Bayarri explaining QUIBIM advantages to interested attendees to EUSOMII – ESOI congress

Besides the opportunity to present the work of our group, we had some remarkable visits to our headquarters, like the visit of Dr. Regina Beets-Tan group together with Dr. Erik Ranschaert (see photo).

Visit of the group of Dr. Regina Beets-Tan and Dr. Erik Ranschaert to QUIBIM headquarters

Visit of the group of Dr. Regina Beets-Tan and Dr. Erik Ranschaert to QUIBIM headquarters

Industry also visited us, in this case it was Agfa Healthcare. The Global Senior Solution Manager, Mr. Chris Townend and the National Sales Manager, José Vicente Puig visited our headquarters and attended the demo of our solution.

Visit of José Vicente Puig (National Sales Manager at Agfa Healthcare) and Chris Townend (Global Senior Solution Manager at Agfa Healthcare)

Visit of José Vicente Puig (National Sales Manager at Agfa Healthcare) and Chris Townend (Global Senior Solution Manager at Agfa Healthcare)

 

The last day we were lucky to have Regina Beets-Tan and Sergey Mozorov, new presidents of ESOI and EUSOMII, respectively, at our headquarters.

 

Visit of Sergey Morozov and Regina Beets-Tan. Photo with QUIBIM founders

Visit of Sergey Morozov and Regina Beets-Tan. Photo with QUIBIM founders

 

The experience speaks by itself.

Summer School on Oncology Imaging Biomarkers

Oncology Imaging Biomarkers

Imaging biomarkers define objective quantitative characteristics extracted from medical images that are related to normal biological processes, clinical endpoints in diseases, or the response to treatment.

In order to develop an imaging biomarker, it is necessary to carry out a series of steps to validate its relation with the reality studied and to check its clinical and technical validity. As we published in 2012 (https://www.ncbi.nlm.nih.gov/pubmed/21733539) and later adopted by the European Society of Radiology (ESR) (https://www.ncbi.nlm.nih.gov/pubmed/23397519), these steps allow for an efficient way of adoption of imaging biomarkers either in clinical routine or clinical trials. This process includes defining tests for the concepts and mechanisms; obtaining standardized and optimized anatomic, functional, and molecular images; analyzing the data with computer models; displaying data appropriately; obtaining the appropriate statistic measures; and conducting tests on the principle, efficacy, and effectiveness. Although important advances are being developed nowadays in the field of image processing algorithms for the extraction of quantitative information from images, the integration of this information in clinical routine requires the existence of validated biomarkers, according to specific protocols for their analysis, in terms of the processing algorithms needed, the models applied and the way the results are generated.

All these topics will be addressed in the upcoming Summer School that we are organising from the 25th to 29th of next July in Valencia under the umbrella of the European Institute for Biomedical Imaging Research (EIBIR). In case you are interested please register to the course and you will enjoy an unforgettable week in Valencia.

Registrations at: http://www.eibir.org/scientific-activities/joint-initiatives/biomedical-image-analysis-platform/eibir-summer-school/2016-2/

 

EIBIR Summer School on Oncology Imaging Biomarkers Poster

EIBIR Summer School on Oncology Imaging Biomarkers